Perceptive Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Perceptive Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-670,206	Closed	-$68.3M	–	111
2023 Q2	$68.3M	Sell	670,206 -1,499,070	-69%	-$142M	1.98%	16
2023 Q1	$197M	Buy	+2,169,276	New	+$127M	5.82%	2
2022 Q4	–	Sell	-100,000	Closed	-$2.51M	–	119
2022 Q3	$2.51M	Buy	+100,000	New	+$2.77M	0.07%	98
2022 Q2	–	Sell	-44,475	Closed	-$1.46M	–	135
2022 Q1	$1.46M	Buy	+44,475	New	+$1.32M	0.03%	122
2018 Q4	–	Sell	-9,677	Closed	-$791K	–	132
2018 Q3	$791K	Buy	+9,677	New	+$682K	0.02%	96

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Perceptive Advisors's RETA Position: Q3 2023 in Review

Perceptive Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 670,206 shares — an estimated $68.3M sold.

Perceptive Advisors first reported a position in RETA in Q3 2018 and held it in 5 quarters. The position peaked at $197M in Q1 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Perceptive Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Perceptive Advisors sold 670,206 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $68.3M.
Perceptive Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 5 quarters.
Perceptive Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $197M in Q1 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Perceptive Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.